Introduction
============

The zotarolimus-eluting stent (ZES), Endeavor^®^ (Medtronic, Minneapolis, MN) and the everolimus-eluting stent (EES), Xience^®^ or Promus™ (Abbott Laboratories, Abbott Park, IL) are second-generation drug-eluting stents with lower target lesion revascularization and adverse event rates than bare metal stents.[@b1-vhrm-8-205]--[@b4-vhrm-8-205]

The ZES and EES stents have been compared in randomized trials with the paclitaxel-eluting stent (Boston Scientific, San Diego, CA) and the sirolimus-eluting stent (Cordis Corporation, Bridgewater, NJ),[@b5-vhrm-8-205]--[@b7-vhrm-8-205] but few comparative data exist between the Endeavor ZES and the EES. Herrador et al[@b8-vhrm-8-205] compared the ZES and EES in coronary bifurcating lesions, and found higher 12-month adverse event and target lesion revascularization rates in the ZES group. Recently, a new ZES, the Resolute™ (Medtronic, Minneapolis, MN) was compared with the EES in a large randomized trial, with no differences in outcomes found between these two stents.[@b9-vhrm-8-205] However, the Resolute ZES had prolonged elution of the drug compared with the Endeavor ZES. Compared with historic controls, the Resolute ZES stent outperformed the Endeavor ZES stent, with superior target lesion and vessel revascularization.[@b10-vhrm-8-205] In this single-center study, we compared the Endeavor ZES and the EES for late outcomes at one year in an unselected consecutive group of patients.

Materials and methods
=====================

Unselected consecutive patients were retrospectively recruited from a single center following stenting with the ZES or the EES. Both de novo and restenotic lesions were included. Patients with bypass graft stenting or who received mixed stents were excluded. The first 100 consecutive patients in each cohort underwent Syntax scoring by an independent investigator blinded to patients' outcomes. The investigator underwent basic training in Syntax scoring using the online tutorial on the Syntax score website (<http://www.syntaxscore.com>) followed by extensive training with an interventional cardiologist experienced in Syntax scoring and having performed over 50 cases with close supervision.

[Tables 1](#t1-vhrm-8-205){ref-type="table"} and [2](#t2-vhrm-8-205){ref-type="table"} show the demographic, clinical, and procedural variables collected by reviewing medical records. Angiographic variables are shown in [Table 2](#t2-vhrm-8-205){ref-type="table"}, and were obtained by independent reviewing of the angiograms by an investigator blinded to patient outcomes. Ejection fraction was obtained from the procedural records as assessed qualitatively during the index procedure using left ventriculography.

Follow-up was limited to one year from the index procedure and was performed using medical records, phone calls, or both. Patients were initially mailed a brief letter describing the protocol, followed by a phone call to obtain verbal consent to be part of the study (using a standardized script approved by our institutional review board). All events reported by patients were verified by cross-reference to medical records. Patients who were deceased had their death certificate retrieved when possible to evaluate the cause of death.

The primary outcome of the study was target vessel failure (defined as cardiac death, non-fatal myocardial infarction, and target vessel revascularization). Secondary outcomes included target lesion revascularization, target vessel revascularization, target lesion failure (defined as cardiac death, non-fatal myocardial infarction, and target lesion revascularization), acute stent thrombosis as defined by the Academic Research Consortium,[@b11-vhrm-8-205] non-fatal myocardial infarction, and cardiac death.

Statistical analysis
--------------------

Descriptive analysis was performed on all variables. The *t*-test was used for continuous variables and Chi-square testing for dichotomous variables. Univariate analysis compared the demographic, clinical, angiographic, and outcome variables between the two groups. Survival analysis (Kaplan-Meier) was performed for target vessel failure over one year of follow-up. SPSS (IBM, New York, NY) software was used to conduct the analysis.

Results
=======

A total of 235 ZES and 208 EES patients met the inclusion criteria and were recruited to the study. Patients were excluded if they refused to give the verbal consent required by the institutional review board (n = 25 ZES, n = 10 EES) or were lost to follow-up (n = 13 ZES, n = 8 EES). A total of 197 ZES patients (270 vessels, 403 segments) and 190 EES patients (306 vessels, 479 segments) were included in the final analysis.

Descriptive analysis for all patients is shown in [Table 1](#t1-vhrm-8-205){ref-type="table"}. There was a high proportion of patients who had had prior percutaneous coronary intervention and prior bypass surgery in both cohorts. Approximately two thirds of the patients were current or prior smokers and 36.5% were diabetics. There were no statistical differences for any of the clinical and demographic variables between the EES and ZES stents, except for a higher incidence of prior myocardial infarction in the EES group (38.9% versus 28.9%; *P* = 0.041) and a higher incidence of cerebrovascular disease in the ZES group (16.2% versus 4.7%; *P* = 0.001). Also, there was no bias regarding utilization of particular stent types at the medical center between the 11 interventionalists, who used the ZES and EES at the same statistical frequency.

Indications for the procedure were similar between the two groups, with about half the patients treated for an acute coronary syndrome. The distribution of disease was also similar between the cohorts, with 6%--10% of patients having had their left main stem treated ([Table 2](#t2-vhrm-8-205){ref-type="table"}). Angiographic and procedural variables are shown in [Table 3](#t3-vhrm-8-205){ref-type="table"}. There was a relatively high number of stents placed per patient (2.8--2.9 stents), and approximately one third of patients had restenotic index lesions. Patients in the EES group had a lower ejection fraction than those in the ZES group (51.5% versus 59.7%, *P* = 0.001); however, ejection fractions were in the normal range in both groups. Long lesion lengths were noted, but were similar in both groups. The Syntax scores for the first 100 consecutive patients, which reflect angiographic complexity, were statistically nearly identical between the EES and ZES (19.6 ± 12.8 versus 20.6 ± 13.6).

At one-year follow-up, target vessel failure was 26.7% for the ZES versus 20.8% for the EES (*P* = 0.19, [Figure 1](#f1-vhrm-8-205){ref-type="fig"}, [Table 4](#t4-vhrm-8-205){ref-type="table"}). The secondary endpoint of target lesion revascularization (20.6% versus 8.9%, *P* = 0.003) was superior for the ZES versus the EES. Target vessel revascularization (26.7% versus 20.8%), cardiac death (2.0% versus 1.6%), non-cardiac death (2.1% versus 1.1%), and definite and probable stent thrombosis (2.5% versus 0%) trended in favor of the EES, but no statistical difference was seen.

Clinical history of patients with definite or probable acute stent thrombosis
-----------------------------------------------------------------------------

Five patients in the ZES cohort had definite or probable stent thrombosis. The first patient was a 92-year-old female with a prior myocardial infarction and a history of hypertension. Stent thrombosis occurred 7 days after the index procedure. She was on clopidogrel and aspirin. She underwent target lesion revascularization but later died during the same hospital stay. The second patient was a 49-year-old male with a prior myocardial infarction, and hyperlipidemia. Stent thrombosis occurred 8 days following the index procedure. He was on clopidogrel and aspirin. He underwent target lesion revascularization successfully. The third patient was a 71-year-old male with history of hyperlipidemia, diabetes mellitus, and prior myocardial infarction. Stent thrombosis occurred 100 days following the index procedure. He was on aspirin and clopidogrel. He underwent target lesion revascularization but later died during the same hospital stay. The fourth patient was a 68-year-old male with a history of hyperlipidemia, prior tobacco use, and diabetes. He was on clopidogrel and aspirin. Stent thrombosis occurred 78 days after the index procedure. He underwent successful target lesion revascularization. The fifth patient was a 65-year-old female with hypertension, hyperlipidemia, diabetes mellitus, and a prior history of smoking. Stent thrombosis occurred at 192 days after the index procedure. She was on clopidogrel and aspirin. She underwent target lesion revascularization successfully.

Discussion
==========

In this study, the primary outcome occurred in 20.8% of the EES versus 26.7% of the ZES (*P* = 0.19) patients, with no differences in the secondary outcome of target vessel revascularization (18.9% versus 25.6%, *P* = 0.142). However, the EES showed superior target lesion revascularization (8.9% versus 20.6%, *P* = 0.003) and target lesion failure (11.7 versus 22.6%, *P* = 0.003) when compared with the ZES. Both the ZES and EES have been shown to have lower target lesion revascularization and adverse event rates than bare metal stents.[@b1-vhrm-8-205]--[@b4-vhrm-8-205] However, not all drug-eluting stents have similar outcomes. In this study, the EES had a superior one-year outcome than the ZES, with less target lesion revascularization and target lesion failure at the one-year follow-up. However, interestingly, target vessel revascularization was the same in both cohorts, resulting in statistically similar target vessel failure. In this retrospective study, there were no predefined endpoints as to when target lesion revascularization could be performed. It is possible that this biased the data in favor of the EES, considering that the ZES is known to have higher late lumen loss than the EES.[@b12-vhrm-8-205]

The ZES has been compared with the sirolimus-eluting stent in randomized trials.[@b5-vhrm-8-205] Insegment binary angiographic restenosis was higher in the ZES cohort (11.7% versus 4.3%, *P* = 0.04). At 9 months, total (clinically and non-clinically driven) target lesion revascularization rates were 9.8% and 3.5% for the ZES and sirolimus-eluting stent groups, respectively (*P* = 0.04). However, clinically driven target lesion revascularization and target vessel failure did not differ significantly between the two stents. Further, the Endeavour ZES has been compared with the paclitaxel-eluting stent in the randomized ENDEAVOR IV trial. This trial showed that the ZES was noninferior to the paclitaxel-eluting stent at the 12-month follow-up, with rates of target vessel failure being 6.6% versus 7.1%, respectively (*P* ≤ 0.001). In Endeavor IV, there were no significant differences between the ZES and the paclitaxel-eluting stent for rates of cardiac death, myocardial infarction, target vessel revascularization, or stent thrombosis.[@b13-vhrm-8-205] At 3-year follow-up, compared with the paclitaxel-eluting stent, the ZES showed reduced target vessel failure (12.3% versus 15.9%, *P* = 0.049) and myocardial infarction rates (2.1% versus 4.9%, *P* = 0.005), with similar ischemia-driven target lesion revascularization (6.5% versus 6.1%, *P* = 0.662).[@b14-vhrm-8-205]

The EES was also compared with the paclitaxel-eluting stent in the SPIRIT III trial. At the 2-year follow-up, compared with the paclitaxel-eluting stent, patients treated with the EES had a significant 32% reduction in target vessel failure (10.7% versus 15.4%, *P* = 0.04) and a 45% reduction in major adverse cardiac events (cardiac death, myocardial infarction, or target lesion revascularization; 7.3% versus 12.8%, *P* = 0.004).[@b7-vhrm-8-205] In the elderly cohort (those \>65 years of age) of SPIRIT III, the EES-treated patients had lower rates of binary insegment restenosis (3.4% versus 15.5%, *P* = 0.004) at 8 months, and a 48% lower incidence of 3-year target vessel failure (10.8% versus 20.8%, *P* = 0.009).[@b15-vhrm-8-205]

However, limited comparative data exist for the Endeavor ZES and the EES. Herrador et al[@b8-vhrm-8-205] compared the ZES with the EES in coronary bifurcating lesions, and found a higher 12-month adverse events rate (23.1% versus 4.5%, *P* \< 0.001) and higher target lesion revascularization (17.5% versus 3.2%, *P* \< 0.001) in the ZES group. Our study included consecutive patients who received EES and ZES from the same medical center. EES outperformed the Endeavor ZES at the one-year follow-up, with less target lesion failure, driven mostly by less target lesion revascularization. However, target vessel failure was similar between the two stents at one year. Recently the new Resolute ZES (Medtronic) was compared with the EES in a large randomized trial and no differences in outcome were found between these two stents.[@b9-vhrm-8-205] However, the Resolute ZES showed prolonged elution of the drug compared with the Endeavor ZES. Furthermore, compared with historic controls, the Resolute ZES stent outperformed the Endeavor stent in data presented recently at the American College of Cardiology scientific sessions.[@b10-vhrm-8-205] The longer drug elution time of zotarolimus seems to be a key factor in reducing target lesion revascularization and target vessel failure in patients treated with ZES stents. The Resolute ZES stent has recently entered the US market and is likely to replace the Endeavor ZES.

Overall, the rates of target lesion revascularization and target vessel failure with the ZES in our study are higher than that in the data published for the Endeavor ZES from the real-world prospective, multicenter E-Five registry.[@b1-vhrm-8-205] The one-year outcome of the Endeavor ZES in the E-Five registry showed a target lesion revascularization rate of 4.5% and definite/probable stent thrombosis of 0.6%. Our data showed a higher target lesion revascularization and stent thrombosis rate than the E-Five registry, likely secondary to the more complex patients treated at our center. Compared with E-Five, our study had more bifurcating lesions (45.6% versus 18.9%), ostial lesions (8.3% versus 5.8%), instent restenosis (33.3% versus 4.8%), left main stenting (6.3% versus 2.4%), and longer total lesion length (54 ± 37.4 versus 18.51 ± 10.61). Furthermore, there were higher clinical risk features in our patients, with more prior percutaneous coronary interventions (67.5% versus 25.3%) and bypass surgeries (21.8% versus 7.5%). As disease complexity increases and major adverse event rates increase, it is more likely that small differences between drug-eluting stents would become more obvious and significant.

Study limitations
-----------------

This study is limited by its retrospective nature. However, angiographic complexity was assessed using Syntax scoring by an investigator blinded to patient outcomes and showed no differences between the two cohorts. Interobserver and intraobserver variability was not determined in this study. However, we utilized a reliable training method recently shown to yield at least moderate agreement in Syntax calculation.[@b16-vhrm-8-205] We also limited Syntax scoring to the first consecutive 100 patients in each cohort. However, the near identical results and similar angiographic variables between the two cohorts predict a low likelihood that differences will emerge in calculating syntax scores for the entire cohort.

It is unlikely that randomized trials will compare the Endeavor ZES with the EES because of the recent introduction of the Resolute ZES to the United States, which has proven superior results to the Endeavor ZES. However, these data continue to be of significance for patients who have already received the ZES and continue to receive the EES.
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![Kaplan-Meier curve showing target vessel failure survival for the Endeavor zotarolimus stent (solid line) versus the Everolimus stent (dashed line).\
**Abbreviation:** TVF, target vessel failure.](vhrm-8-205f1){#f1-vhrm-8-205}

###### 

Demographic and clinical variables

                                                     n         Zotarolimus   n         Everolimus    *P* value
  -------------------------------------------------- --------- ------------- --------- ------------- -----------
  Age (years)                                        197       66.9 ± 12.2   189       65.7 ± 11.4   0.300
  Body mass index                                    197       30.5 ± 6.9    187       30.9 ± 6.6    0.587
  Male (%)                                           133/197   67.5          126/190   66.3          0.829
  New York Heart Association class (%)               197                     189                     0.208
  No symptoms/Class I                                155       78.7          158       83.6          
  Class II                                           23        11.7          26        13.8          
  Class III                                          7         3.6           3         1.6           
  Class IV                                           12        6.1           2         1.1           
  Prior percutaneous coronary intervention (%)       133/197   67.5          142/189   75.1          0.115
  Prior coronary artery bypass surgery (%)           43/197    21.8          47/190    24.7          0.548
  Previous myocardial infarction (%)                 57/197    28.9          74/190    38.9          0.041
  Family history of premature coronary disease (%)   97/197    49.2          75/186    40.3          0.082
  Renal failure (%)                                  11/197    5.6           8/186     4.3           0.642
  Peripheral vascular disease (%)                    30/197    15.2          21/190    11.1          0.233
  History of hypertension (%)                        151/197   76.6          153/190   80.5          0.387
  Cerebrovascular disease (%)                        32/197    16.2          2/190     4.7           0.001
  Hyperlipidemia (%)                                 166/197   84.3          161/190   84.7          1.000
  History of smoking (current and ex-smoker, %)      129/197   65.5          121/189   64            0.831
  Diabetes mellitus (%)                              72/197    36.5          70/189    37            1.000

###### 

Indications for angiography and coronary artery distribution

                                                                                Zotarolimus   Everolimus   *P* value
  ----------------------------------------------------------------------------- ------------- ------------ -----------
  Indications for angiography (%)                                                                          0.979
  Unstable angina/NSTEMI                                                        43.5          49.8         
  STEMI                                                                         4.8           2.4          
  Abnormal perfusion test with symptoms                                         17.7          15.3         
  Abnormal perfusion test with no symptoms                                      6.7           6.2          
  Cardiomyopathy/ congestive heart failure                                      1.4           0.5          
  Staged intervention                                                           23.4          23.9         
  Arrhythmias                                                                   1.4           0.9          
  Recent decrease in ejection fraction                                          0             1            
  Progressive dyspnea                                                           1             0            
  Number of patients treated (n)                                                197           190          
  Number of vessels treated (n)[\*](#tfn2-vhrm-8-205){ref-type="table-fn"}      270           306          
  Number of segments treated (n)[\*\*](#tfn3-vhrm-8-205){ref-type="table-fn"}   403           479          
  Distribution of coronary artery disease (per number of vessels, %)                                       0.835
  Right coronary artery                                                         24.8          20.9         
  Left main stem                                                                6.3           9.8          
  Left anterior descending artery                                               35.4          35.9         
  Ramus intermedius                                                             4.4           4.6          
  Left circumflex                                                               29.1          28.8         

**Notes:**

The following were considered vessels per patient and counted when treated: LAD, LCX, RI, RCA, and LM;

The following segments were considered per vessel and counted when treated: LAD, proximal, mid, distal, diagonal 1 and 2; LCX, proximal, distal, obtuse marginal 1 and 2, and posterolateral branch 1 and 2 RCA, proximal, mid, distal, acute marginal, posterior descending artery, posterolateral 1 and 2. Disease in LM and RI was considered as one segment per vessel.

**Abbreviations:** STEMI, ST elevation myocardial infarction; NSTEMI, non-ST elevation myocardial infarction; RI, ramus intermedius; LCX, left circumflex; LM, left main stem; LAD, left anterior descending; RCA, right coronary artery.

###### 

Angiographic and procedural variables

                                                                      Zotarolimus             Everolimus             *P* value
  ------------------------------------------------------------------- ----------------------- ---------------------- -----------
  Per patient analysis                                                n = 197                 n = 190                
  Ejection fraction (%)                                               59.7 ± 13.2 (n = 101)   51.5 ± 143 (n = 152)   0.001
  Stents used per patient (n)                                         2.8 ± 1.8               2.9 ± 2.1              0.690
  Length of disease treated per patient (mm)                          54 ± 37.4               52.2 ± 43              0.698
  Patients treated with restenotic lesions (%)                        33.3                    42.6                   0.104
  Percentage of patients with non-left main bifurcating disease (%)   45.6                    50.8                   0.422
  Syntax (first 100 consecutive patient in each group)                19.6 ± 12.8             20.6 ± 13.6            0.592
  Per vessel analysis                                                 n = 270                 n = 306                
  Stents used per vessel (n)                                          1.8 ± 1.2               1.8 ± 1.2              0.880
  Length of disease treated per vessel (mm)                           34.5 ± 25.2             32.4 ± 26.4            0.371
  Per segment analysis                                                n = 403                 n = 479                
  Pre lesion severity (%)                                             71.7 ± 25.1             84.5 ± 11.9            0.001
  Post lesion severity (%)                                            0.2 ± 2                 0                      0.103
  Diameter (mm)                                                       2.8 ± 0.4               3 ± 0.5                0.001
  Stents used per segment (n)                                         1.1 ± 0.5               1.2 ± 0.4              0.029
  Length of disease treated per segment (mm)                          20.9 ± 9.5              20.7 ± 12.6            0.777
  Segments treated with restenotic lesions (%)                        28.7                    33.9                   0.128
  Ostial segments treated (%)                                         8.3                     8.2                    1.000

###### 

Patient outcomes

                                                                               Zotarolimus    Everolimus     *P* value
  ---------------------------------------------------------------------------- -------------- -------------- -----------
  Duration of follow-up (days)                                                 350.9 ± 55.8   344.6 ± 70.5   0.001
  TLR per segment (%)                                                          14.4           6.1            0.001
  TLR per vessel (%)                                                           17             7.9            0.002
  TLR per patient (%)                                                          20.6           8.9            0.003
  TLR per segment (%)                                                          16.7           9.5            0.002
  TLR per vessel (%)                                                           20.8           14.5           0.059
  TLR per patient (%)                                                          25.6           18.9           0.142
  Target lesion failure (%)                                                    22.6           11.7           0.003
  Target vessel failure (%)                                                    26.7           20.8           0.19
  Stent thrombosis (%)                                                                                       NA
  Definite or probable                                                         2.5            0              
  Possible                                                                     0.5            0.5            
  Patient on clopidogrel at definite or probable stent thrombosis event (%)    100            0              NA
  Patient compliance when definite or probably stent thrombosis occurred (%)   100            0              NA
  Percent of patients on clopidogrel on follow-up (%)                          95.9           93.1           0.256
  Percent of patients on aspirin on follow-up (%)                              94.3           97.7           0.118
  **Death classification on follow-up (%)**                                                                  
  No                                                                           94.9           96.8           NA
  Non-cardiac                                                                  2.1            1.1            
  Unknown                                                                      1              0.5            
  Cardiac sudden death probable                                                1              0              
  Cardiac non-stent thrombosis                                                 1              1.6            
  Acute non-ST elevation myocardial infarction, non-fatal (%)                  3.6            1.1            0.176
  Acute ST elevation myocardial infarction, non-fatal (%)                      0              1.6            0.118

**Abbreviations:** NA, not applicable; TLR, Target lesion revascularization.
